For the first quarter of 2016 ended on March 31, Johnson & Johnson recorded sales of $17.5 billion, up 0.6 percent as compared to the first quarter of the previous year. Excluding acquisitions, divestitures and sales of drugs related to hepatitis C, worldwide sales rose by 6.9 percent on an operational basis, with sales climbing by 9.8 percent in the U.S. and by 3.8 percent in other markets around the world.

In particular, the U.S. healthcare giant's medical devices business, which includes Vision Care, saw a decline of 6.5 percent in terms of dollars in its international sales to $3.1 billion and an increase of 2.2 percent to $3.0 billion in domestic sales during the first three months of this year.

Worldwide sales for the company's Vision Care unit, encompassing Acuvue contact lenses, grew by 1.4 percent to $640 million in the first quarter, consisting of $242 million in U.S. sales, down 4.3 percent, and $398 million in international sales, up 5.3 percent. Excluding acquisitions and divestitures, Vision Care posted an increase of 1.9 percent in operational sales worldwide as a result of the growth in international sales of Acuvue contact lenses. U.S. and international sales rose by 4.1 percent and 0.5 percent, respectively.